Attovia Therapeutics (ATTO) major holder converts 18.2M preferred into common
Rhea-AI Filing Summary
Attovia Therapeutics, Inc. insider Deep Track Biotechnology Master Fund, Ltd. reported the automatic conversion of Series C Redeemable Convertible Preferred Stock into common stock in connection with the closing of Attovia’s initial public offering. 18,181,818 preferred shares converted into 1,957,138 common shares at a 9.29-for-one ratio, resulting in 1,957,138 common shares held directly. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but each disclaims beneficial ownership beyond their respective pecuniary interests.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,957,138 shares
Net Buy
2 txns
Insider
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, KROIN DAVID
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series C Redeemable Convertible Preferred Stock F1, F2 | 18,181,818 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F2 | 1,957,138 | -- | -- |
Holdings After Transaction:
Series C Redeemable Convertible Preferred Stock — 0 shares (Direct);
Common Stock — 1,957,138 shares (Direct)
Footnotes (2)
- F1. Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.
- F2. Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.
Key Figures
Series C preferred shares converted: 18,181,818 shares
Common shares received: 1,957,138 shares
Conversion ratio: 9.29-for-one
+1 more
4 metrics
Series C preferred shares converted
18,181,818 shares
Automatic conversion of Series C Redeemable Convertible Preferred Stock upon IPO closing
Common shares received
1,957,138 shares
Common stock issued to Deep Track Biotechnology Master Fund, Ltd. from preferred conversion
Conversion ratio
9.29-for-one
Each share of Series C Redeemable Convertible Preferred Stock converted into common stock
Common shares held after conversion
1,957,138 shares
Direct ownership reported following the conversion transaction
Key Terms
Series C Redeemable Convertible Preferred Stock, initial public offering, conversion ratio, pecuniary interests
4 terms
Series C Redeemable Convertible Preferred Stock financial
"Each share of Series C Redeemable Convertible Preferred Stock automatically converted"
initial public offering financial
"automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
conversion ratio financial
"upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one"
The conversion ratio is the number of common shares an investor receives when a convertible security (like a bond or preferred share) or an exchangeable instrument is turned into ordinary stock. It matters because it tells investors how much ownership or dilution will occur — similar to knowing how many slices you get when you trade in a coupon — and directly affects the value you get from the convertible and the company’s future share count.
pecuniary interests financial
"disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests"
FAQ
What insider transaction did Attovia Therapeutics (ATTO) report on this Form 4?
Deep Track Biotechnology Master Fund, Ltd. reported an automatic conversion of Series C Redeemable Convertible Preferred Stock into Attovia common stock upon the IPO closing, receiving 1,957,138 common shares from 18,181,818 preferred shares.
What is Deep Track Biotechnology Master Fund, Ltd.’s resulting Attovia (ATTO) common stock holding?
After the reported conversion, Deep Track Biotechnology Master Fund, Ltd. holds 1,957,138 shares of Attovia common stock directly. This position reflects the automatic conversion of its Series C preferred shares at the IPO-related conversion ratio.
Who are the reporting persons on the Attovia Therapeutics (ATTO) Form 4 and what are their roles?
The reporting persons are Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, and David Kroin. Deep Track Capital, LP manages the fund, and Mr. Kroin is managing member of the fund’s general partner, with each disclaiming beneficial ownership beyond pecuniary interests.
Was the Attovia Therapeutics (ATTO) Form 4 transaction a market buy or sell?
No market buy or sell is reported. The Form 4 describes an automatic conversion of preferred stock into common stock upon Attovia’s IPO closing, a structural change in security form rather than an open-market purchase or sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
